SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$155M
Q4 2021
Positions
67
Filings on Record
39
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Birchview Capital, LP reported $155M in U.S.-listed holdings across 67 positions for Q4 2021.

The portfolio is heavily concentrated: BMY alone accounts for 30.8% of reported value.

Compared with Q3 2021, the fund opened 6 new positions and exited 3.

Portfolio Metrics

Turnover
+9.2%
vs prior filed quarter
Top-10 Concentration
+70.2%
share of reported value
Largest Position
+30.8%
Bristol Myers Squibb
New / Exited
6 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 82.7%Other: 17.3%
  • Common Stock · 82.7% · $128M
  • Other · 17.3% · $27M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
INBXUSDINHIBRX INCNEW+40.0K40.0K+$2M$2M
TSVT*2SEVENTY BIO INCNEW+28.0K28.0K+$718,000$718,000
VTYXUSDVENTYX BIOSCIENCES INCNEW+25.0K25.0K+$497,000$497,000
SILKUSDSILK ROAD MEDICAL INCNEW+8.0K8.0K+$341,000$341,000
PFEPFIZER INCNEW+4.0K4.0K+$236,000$236,000
DCGODOCGO INCNEW+10.0K10.0K+$94,000$94,000
ELUTAZIYO BIOLOGICS INCADDED+1.37M1.42M+$8M$8M
AVEO PHARMACEUTICALS INCADDED+100.0K140.0K+$410,000$657,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM30.80%$48M766.1K
2ACCELERATE DIAGNOSTICS INCCOM7.57%$12M2.25M
3ELUTAZIYO BIOLOGICS INChistory →COM5.39%$8M1.42M
4QDEL*QUIDEL CORPhistory →COM5.20%$8M59.7K
5NBIXNEUROCRINE BIOSCIENCES INChistory →COM4.90%$8M89.2K
6FHTXFOGHORN THERAPEUTICS INChistory →COM4.63%$7M314.1K
7BIODESIX INCCOM4.27%$7M1.25M
8ACADACADIA PHARMACEUTICALS INChistory →COM3.00%$5M199.4K
9UTHUNITED THERAPEUTICS CORPhistory →COM2.51%$4M18.0K
10BIIBBIOGEN INChistory →COM1.95%$3M12.6K
11BDQMALBIREO PHARMA INChistory →COM1.70%$3M113.0K
12MASI*MASIMO CORPhistory →COM1.51%$2M8.0K
13ARNAEURARENA PHARMACEUTICALS INChistory →COM1.32%$2M22.0K
14PROTHENA CORP PLCSHS1.28%$2M40.2K
15INBXUSDINHIBRX INChistory →COM1.13%$2M40.0K
16CLRUSDCONTINENTAL RESOURCES INChistory →COM1.11%$2M38.6K
17BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM1.07%$2M12.0K
18KPTIEURKARYOPHARM THERAPEUTICS INChistory →COM1.02%$2M246.0K
19HROWHARROW HEALTH INChistory →COM1.00%$2M180.0K
20IMGNEURIMMUNOGEN INCCOM0.91%$1M190.0K
21ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.89%$1M133.1K
22NKTREURNEKTAR THERAPEUTICSCOM0.87%$1M100.0K
23PTGXPROTAGONIST THERAPEUTICS INCCOM0.84%$1M38.0K
24ARVNARVINAS INCCOM0.79%$1M15.0K
25ALKERMES PLCSHS0.75%$1M50.0K
26OVVOVINTIV INCCOM0.74%$1M34.2K
27CYTKCYTOKINETICS INCCOM0.74%$1M25.0K
28GOSSGOSSAMER BIO INCCOM0.73%$1M100.0K
29AMARIN CORP PLCSPONS ADR NEW0.65%$1M300.0K
30HTDCORCEPT THERAPEUTICS INCCOM0.64%$990,00050.0K
31VNDAVANDA PHARMACEUTICALS INCCOM0.61%$941,00060.0K
32BLUEBIRD BIO INCCOM0.54%$839,00084.0K
33PGNYPROGYNY INCCOM0.49%$755,00015.0K
34CCXIEURCHEMOCENTRYX INCCOM0.47%$728,00020.0K
35TSVT*2SEVENTY BIO INCCOM0.46%$718,00028.0K
36CGEMCULLINAN ONCOLOGY INCCOM0.45%$696,00045.1K
37PXDEURPIONEER NATURAL RESOURCES COCOM0.45%$691,0003.8K
38ZNTLZENTALIS PHARMACEUTICALS INCCOM0.43%$672,0008.0K
39AVEO PHARMACEUTICALS INCCOM0.42%$657,000140.0K
40INARI MEDICAL INCCOM0.41%$639,0007.0K
41APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.37%$567,00012.0K
424XC1KALVISTA PHARMACEUTICALS INCCOM0.34%$529,00040.0K
43CFRXEURCONTRAFECT CORPCOM0.34%$526,000200.0K
44VTYXUSDVENTYX BIOSCIENCES INCCOM0.32%$497,00025.0K
45XNCRXENCOR INCCOM0.32%$493,00012.3K
46IRTCIRHYTHM TECHNOLOGIES INCCOM0.30%$471,0004.0K
47AM6AMICUS THERAPEUTICS INCCOM0.28%$439,00038.0K
48GTHXEURG1 THERAPEUTICS INCCOM0.26%$408,00040.0K
49TURNING POINT THERAPEUTICS INCCOM0.25%$382,0008.0K
50STOKSTOKE THERAPEUTICS INCCOM0.23%$360,00015.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.